Trained innate immunity and atherosclerosis

Current Opinion in Lipidology

Volumn 24, Issue 6, 2013, Pages 487-492

  Bekkering, Siroon ^a   Joosten, Leo A B ^a   Van Der Meer, Jos W M ^a   Netea, Mihai G ^a   Riksen, Niels P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

atherosclerosis; epigenetic modification; inflammation; innate immunity

Indexed keywords

3 DEAZANEPLANOCIN A; APOLIPOPROTEIN B; BCG VACCINE; CHEMOKINE; CYTOKINE; HISTONE; LOW DENSITY LIPOPROTEIN; N (1 BENZYL 4 PIPERIDINYL) 2 (HEXAHYDRO 4 METHYL 1H 1,4 DIAZEPIN 1 YL) 6,7 DIMETHOXY 4 QUINAZOLINAMINE;

ATHEROGENESIS; ATHEROSCLEROSIS; B LYMPHOCYTE; BCG VACCINATION; CYTOKINE PRODUCTION; DIET; ENVIRONMENTAL FACTOR; EPIGENETICS; GENE EXPRESSION; HISTONE METHYLATION; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; MACROPHAGE; MONOCYTE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TRANSCRIPTION REGULATION; TUBERCULOSIS;

CANDIDA ALBICANS;

ANIMALS; ATHEROSCLEROSIS; HUMANS; IMMUNITY, INNATE; MONOCYTES;

EID: 84888292720     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000023     Document Type: Review

References (67)

1. Alwan A, Armstrong T, Bettcher D, et al. Global status report on noncommunicable diseases. Geneva, Switzerland: World Health Organization; 2011.
2. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011; 12:204-212.
3. Netea MG, Quintin J, van der Meer JW. Trained immunity: A memory for innate host defense. Cell Host Microbe 2011; 9:355-361.
4. Kleinnijenhuis J, Quintin J, Preijers F, et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci U S A 2012; 109: 17537-17542. Series of in-vitro and human in-vivo studies reporting that BCG vaccination can induce long-term activation of monocytes via epigenetic reprogramming
5. Quintin J, Saeed S, Martens JH, et al. Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes. Cell Host Microbe 2012; 12:223-232. Series of animal studies and in-vitro studies demonstrating that C. albicans can induce functional reprogramming of monocytes via increased histone trimethylation
6. Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell 2001; 104:503-516.
7. Braunersreuther V, Zernecke A, Arnaud C, et al. Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2007; 27:373-379.
8. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998; 394:894-897.
9. Gu L, Okada Y, Clinton SK, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998; 2:275-281.
10. Johnson JL, Newby AC. Macrophage heterogeneity in atherosclerotic plaques. Curr Opin Lipidol 2009; 20:370-378.
11. Kunjathoor VV, Febbraio M, Podrez EA, et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem 2002; 277:49982-49988.
12. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: A possible pathway for plaque activation. Circulation 2002; 105:1158-1161.
13. Bjorkbacka H, Kunjathoor VV, Moore KJ, et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 2004; 10:416-421.
14. Kirii H, Niwa T, Yamada Y, et al. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2003; 23:656-660.
15. Stewart CR, Stuart LM, Wilkinson K, et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 2010; 11:155-161.
16. Chavez-Sanchez L, Madrid-Miller A, Chavez-Rueda K, et al. Activation of TLR2 and TLR4 by minimally modified low-density lipoprotein in human macrophages and monocytes triggers the inflammatory response. Hum Immunol 2010; 71:737-744.
17. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010; 464:1357-1361.
18. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 2011; 145:341-355.
19. Swirski FK, Nahrendorf M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science 2013; 339:161-166. Excellent review on the role of leukocytes in atherosclerosis
20. Jaskiewicz M, Conrath U, Peterhansel C. Chromatin modification acts as a memory for systemic acquired resistance in the plant stress response. EMBO Rep 2011; 12:50-55.
21. vant Wout JW, Poell R, van Furth R. The role of BCG/PPD-activated macrophages in resistance against systemic candidiasis in mice. Scand J Immunol 1992; 36:713-719.
22. Sakuma T, Suenaga T, Yoshida I, Azuma M. Mechanisms of enhanced resistance of Mycobacterium bovis BCG-treated mice to ectromelia virus infection. Infect Immun 1983; 42:567-573.
23. Aaby P, Benn CS. Saving lives by training innate immunity with bacille Calmette- Guerin vaccine. Proc Natl Acad Sci U S A 2012; 109:17317-17318.
24. Jaenisch R, Bird A. Epigenetic regulation of gene expression: How the genome integrates intrinsic and environmental signals. Nat Genet 2003; 33 (Suppl):245-254.
25. Webster AL, Yan MS, Marsden PA. Epigenetics and cardiovascular disease. Can J Cardiol 2013; 29:46-57.
26. Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotechnol 2010; 28:1069-1078.
27. Greer EL, Shi Y. Histone methylation: A dynamic mark in health, disease and inheritance. Nat Rev Genet 2012; 13:343-357.
28. Zlatanova J, Leuba SH, van Holde K. Chromatin structure revisited. Crit Rev Eukaryot Gene Expr 1999; 9:245-255.
29. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128:693-705.
30. Wen H, Dou Y, Hogaboam CM, Kunkel SL. Epigenetic regulation of dendritic cell-derived interleukin-12 facilitates immunosuppression after a severe innate immune response. Blood 2008; 111:1797-1804.
31. GarlyML, Martins CL, Bale C, et al. BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa. A nonspecific beneficial effect of BCG? Vaccine 2003; 21:2782-2790.
32. Lamb DJ, Eales LJ, Ferns GA. Immunization with bacillus Calmette-Guerin vaccine increases aortic atherosclerosis in the cholesterol-fed rabbit. Atherosclerosis 1999; 143:105-113.
33. Lamb DJ, El-Sankary W, Ferns GA. Molecular mimicry in atherosclerosis: A role for heat shock proteins in immunisation. Atherosclerosis 2003; 167:177-185.
34. Lamb DJ, Ferns GA. The magnitude of the immune response to heat shock protein-65 following BCG immunisation is associated with the extent of experimental atherosclerosis. Atherosclerosis 2002; 165:231-240.
35. Standaert-Vitse A, Jouault T, Vandewalle P, et al. Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn's disease. Gastroenterology 2006; 130:1764-1775.
36. Cinemre H, Bilir C, Gokosmanoglu F, Kadakal F. Anti-Saccharomyces cerevisiae antibodies in acute myocardial infarction. J Investig Med 2007; 55:444-449.
37. Nagi-Miura N, Harada T, Shinohara H, et al. Lethal and severe coronary arteritis in DBA/2 mice induced by fungal pathogen, CAWS, Candida albicans water-soluble fraction. Atherosclerosis 2006; 186:310-320.
38. Rosenfeld ME, Campbell LA. Pathogens and atherosclerosis: Update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. Thromb Haemost 2011; 106:858-867.
39. Krull M, Klucken AC, Wuppermann FN, et al. Signal transduction pathways activated in endothelial cells following infection with Chlamydia pneumoniae. J Immunol 1999; 162:4834-4841.
40. Netea MG, Selzman CH, Kullberg BJ, et al. Acellular components of Chlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells. Eur J Immunol 2000; 30:541-549.
41. Kalayoglu MV, Byrne GI. Induction of macrophage foam cell formation by Chlamydia pneumoniae. J Infect Dis 1998; 177:725-729.
42. Selzman CH, Netea MG, Zimmerman MA, et al. Atherogenic effects of Chlamydia pneumoniae: Refuting the innocent bystander hypothesis. J Thorac Cardiovasc Surg 2003; 126:688-693.
43. Blessing E, Campbell LA, Rosenfeld ME, Kuo CC. Chlamydia pneumoniae and hyperlipidemia are co-risk factors for atherosclerosis: Infection prior to induction of hyperlipidemia does not accelerate development of atherosclerotic lesions in C57BL/6J mice. Infect Immun 2002; 70:5332-5334.
44. Elkind MS, Luna JM, Moon YP, et al. Infectious burden and carotid plaque thickness: The northern Manhattan study. Stroke 2010; 41:E117-e122.
45. Smieja M, Gnarpe J, Lonn E, et al. Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2003; 107:251-257.
46. Elkind MS, Ramakrishnan P, Moon YP, et al. Infectious burden and risk of stroke: The northern Manhattan study. Arch Neurol 2010; 67:33-38.
47. Watson C, Alp NJ. Role of Chlamydia pneumoniae in atherosclerosis. Clin Sci (Lond) 2008; 114:509-531.
48. Wierda RJ, Geutskens SB, Jukema JW, et al. Epigenetics in atherosclerosis and inflammation. J Cell Mol Med 2010; 14 (6A):1225-1240.
49. Sharma P, Kumar J, Garg G, et al. Detection of altered global DNA methylation in coronary artery disease patients. DNA Cell Biol 2008; 27:357-365.
50. Stenvinkel P, Karimi M, Johansson S, et al. Impact of inflammation on epigenetic DNA methylation - a novel risk factor for cardiovascular disease? J Intern Med 2007; 261:488-499.
51. Schleithoff C, Voelter-Mahlknecht S, Dahmke IN, Mahlknecht U. On the epigenetics of vascular regulation and disease. Clin Epigenetics 2012; 4:7.
52. Dje N'Guessan P, Riediger F, Vardarova K, et al. Statins control oxidized LDLmediated histone modifications and gene expression in cultured human endothelial cells. Arterioscler Thromb Vasc Biol 2009; 29:380-386.
53. Schmeck B, Beermann W, N' Guessan DN, et al. Simvastatin reduces Chlamydophila pneumoniae-mediated histone modifications and gene expression in cultured human endothelial cells. Circ Res 2008; 102:888-895.
54. Yan MS, Matouk CC, Marsden PA. Epigenetics of the vascular endothelium. J Appl Physiol 2010; 109:916-926.
55. Ho JJ, Man HS, Marsden PA. Nitric oxide signaling in hypoxia. J Mol Med (Berl) 2012; 90:217-231.
56. Hastings NE, Simmers MB, McDonald OG, et al. Atherosclerosis-prone hemodynamics differentially regulates endothelial and smooth muscle cell phenotypes and promotes pro-inflammatory priming. Am J Physiol Cell Physiol 2007; 293:C1824-C1833.
57. Chen W, Bacanamwo M, Harrison DG. Activation of p300 histone acetyltransferase activity is an early endothelial response to laminar shear stress and is essential for stimulation of endothelial nitric-oxide synthase mRNA transcription. J Biol Chem 2008; 283:16293-16298.
58. Liu L, Li Y, Tollefsbol TO. Gene-environment interactions and epigenetic basis of human diseases. Curr Issues Mol Biol 2008; 10:25-36.
59. Adcock IM. Histone deacetylase inhibitors as novel anti-inflammatory agents. Curr Opin Investig Drugs 2006; 7:966-973.
60. Cole PA. Chemical probes for histone-modifying enzymes. Nat Chem Biol 2008; 4:590-597.
61. Nebbioso A, Carafa B, Benedetti R, Altucci L. Trials with epigenetic' drugs: An update. Mol Oncol 2012; 6:657-682.
62. Choi JH, Nam KH, Kim J, et al. Trichostatin A exacerbates atherosclerosis in low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2005; 25:2404-2409.
63. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3:415-428.
64. Li TW, Yang H, Peng H, et al. Effects of S-adenosylmethionine and methylthioadenosine on inflammation-induced colon cancer in mice. Carcinogenesis 2012; 33:427-435.
65. Araki K, Turner AP, Shaffer VO, et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009; 460:108-112.
66. Wei G, Wei L, Zhu J, et al. Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells. Immunity 2009; 30:155-167.
67. Biancotto C, Frige G, Minucci S. Histone modification therapy of cancer. Adv Genet 2010; 70:341-386.